The introduction of inhibitors HMG-CoA reductase offers a new approach to treatment of hypercholesterolemia. In this study total of 66 patients, saffering of hypercholesterolemia included. They are divided in two groups (35 patients with Lovastation treated and 31 without treatment). All patients was undergo clinical examination and therapeutic efficiency evaluated after 16 weeks (control per all 4 weeks). There were no statistically significant difference noticed in age, gender, tobaco consumptionand alcohol consumption and cholesterolemia parameter levels in baseline measures between groups (p 0.05). The partial corelation showed the statistically levels in the Lovastation treated group (p 0.001). When testing duration of therapy effect there appeared statistically significant difference between two tested groups, in all parametres of hypercholesterolemia (p 0.001). This maior reduction in LDL-C level and increase HDL-C level by Lovastation therapy may be valuable for prevention of CHR and the development of atherosclerosis. In the patients with primary hypercholesterolemia.